Citadel Advisors’s Sonnet BioTherapeutics SONN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-46,082
| Closed | -$211K | – | 13972 |
|
|
2025
Q3 | $211K | Buy |
+46,082
| New | +$204K | ﹤0.01% | 11159 |
|
|
2025
Q1 | – | Sell |
-24,013
| Closed | -$35.1K | – | 15492 |
|
|
2024
Q4 | $35.1K | Buy |
+24,013
| New | +$83.8K | ﹤0.01% | 12732 |
|
|
2024
Q1 | – | Sell |
-3,681
| Closed | -$51.2K | – | 15379 |
|
|
2023
Q4 | $51.2K | Buy |
+3,681
| New | +$50.1K | ﹤0.01% | 11759 |
|
|
2022
Q3 | – | Sell |
-6
| Closed | -$4K | – | 13543 |
|
|
2022
Q2 | $4K | Sell |
6
-159
| -96% | -$114K | ﹤0.01% | 12693 |
|
|
2022
Q1 | $153K | Buy |
+165
| New | +$140K | ﹤0.01% | 11839 |
|
|
2021
Q2 | – | Sell |
-46
| Closed | -$255K | – | 14370 |
|
|
2021
Q1 | $255K | Buy |
+46
| New | +$291K | ﹤0.01% | 11192 |
|
|
2020
Q1 | – | Hold |
0
| – | -$14K | – | 10127 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 8983 |
|
|
2019
Q2 | – | Sell |
-1
| Closed | -$80K | – | 9799 |
|
|
2019
Q1 | $80K | Buy |
+1
| New | +$117K | ﹤0.01% | 8637 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 8665 |
|
|
2017
Q1 | – | Hold |
0
| – | -$17K | – | 7997 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 7113 |
|
|
2016
Q3 | – | Hold |
0
| – | -$15K | – | 7733 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 6688 |
|
|
2015
Q3 | – | Hold |
0
| – | -$90K | – | 9202 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 7182 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 7623 |
|
Other funds holding SONN
Citadel Advisors's SONN Position: Q4 2025 in Review
Citadel Advisors sold out of Sonnet BioTherapeutics (SONN) in Q4 2025, closing a stake of 46,082 shares — an estimated $211K sold.
Citadel Advisors first reported a position in SONN in Q1 2019 and held it in 7 quarters. The position peaked at $255K in Q1 2021. 1 fund tracked by Wall St. Rank holds SONN as of Q4 2025.
- Citadel Advisors reported no remaining Sonnet BioTherapeutics position as of Q4 2025 after selling out during the quarter.
- Citadel Advisors sold 46,082 Sonnet BioTherapeutics shares in Q4 2025, an estimated $211K.
- Citadel Advisors first reported a position in Sonnet BioTherapeutics in Q1 2019 and held it in 7 quarters.
- Citadel Advisors's Sonnet BioTherapeutics position peaked at $255K in Q1 2021.
- 1 fund tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2025.
Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.